Recently, the State Drug Administration passed a priority review and approval process to approve the marketing of Avcatel tablets, a Class 1 innovative drug declared by Cytokinetics, Incorporated. The drug is used to treat adult patients with obstructive hypertrophic cardiomyopathy in the New York Heart Association's grade II-III cardiac function rating to improve exercise capacity and symptoms. The launch of this drug provides patients with new treatment options.

Recently, the State Drug Administration passed a priority review and approval process to approve the marketing of Avcatel tablets, a Class 1 innovative drug declared by Cytokinetics, Incorporated. The drug is used to treat adult patients with obstructive hypertrophic cardiomyopathy in the New York Heart Association's grade II-III cardiac function rating to improve exercise capacity and symptoms. The launch of this drug provides patients with new treatment options.